OIP5 and adenocarcinoma: Recently, it has found that OIP5-AS1, as a novel lncRNA, is abnormally expressed in multiple tumors and can be used as a clinical biomarker for liver hepatocellular carcinoma and adenocarcinoma [16, 17].